News

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer.

Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With a deep background in working across multiple therapeutic areas and successfully leading organizations through regulatory approvals, Dr. Matkovits will play a critical role in Kaléo’s continued expansion and development of the company’s innovative Aerio™ Auto-Injector Platform. Her appointment comes at an exciting time for Kaléo, which recently secured key contracts with the U.S. Department of Defense and the Department of Health and Human Services, further strengthening the company’s role in providing medical countermeasures.

“Theresa’s extensive experience in leading global drug development and commercialization will be a key asset as we continue to leverage our innovative product portfolio to expand our medical countermeasures business,” said Michael Wells, Chairman and Chief Executive Officer of Kaléo. “Her proven ability to navigate regulatory landscapes and drive operational excellence makes her an outstanding addition to our executive team.”

Prior to joining Kaléo, Dr. Matkovits served as Chief Development Officer for Matinas Biopharma, where she led the company’s clinical-stage asset and secured strategic partnerships with key organizations such as the NIH and the Cystic Fibrosis Foundation. Throughout her extensive career, she has held leadership positions at NPS Pharmaceuticals, The Medicines Company, and Novartis, making significant contributions to drug development, regulatory advocacy, and commercialization efforts.

Read more here.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …